Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2014

01-02-2014 | Clinical Trial

Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers

Authors: Jennifer T. Loud, Gretchen L. Gierach, Timothy D. Veenstra, Roni T. Falk, Kathryn Nichols, Allison Guttmann, Xia Xu, Mark H. Greene, Mitchell H. Gail

Published in: Breast Cancer Research and Treatment | Issue 3/2014

Login to get access

Abstract

Accurately quantifying parent estrogens (PE) estrone (E1) and estradiol (E2) and their metabolites (EM) within breast tissue and serum may permit detailed investigations of their contributions to breast carcinogenesis among BRCA1/2 mutation carriers. We conducted a study of PE/EM in serum, nipple aspirate fluid (NAF), and ductal lavage supernatant (DLS) among postmenopausal BRCA1/2 mutation carriers. PE/EM (conjugated and unconjugated) were measured in paired serum/NAF (n = 22 women) and paired serum/DLS samples (n = 24 women) using quantitative liquid chromatography–tandem mass spectrometry (LC/MS/MS). The relationships between serum and tissue-specific PE/EM were measured using Pearson’s correlation coefficients. Conjugated forms of PE/EM constituted the majority of estrogen in serum (88 %), NAF (59 %) and DLS (69 %). PE/EM in NAF and serum were highly correlated [E1 (r = 0.97, p < 0.0001), E2 (r = 0.90, p < 0.0001) and estriol (E3) (r = 0.74, p < 0.0001)] as they were in DLS and serum [E1 (r = 0.92, p < 0.0001; E2 (r = 0.70, p = 0.0001; E3 (r = 0.67, p = 0.0004)]. Analyses of paired total estrogen values for NAF and serum, and DLS and serum yielded ratios of 0.22 (95 % CI 0.19–0.25) and 0.28 (95 % CI 0.24–0.32), respectively. This report is the first to employ LC/MS/MS to quantify PE/EM in novel breast tissue-derived biospecimens (i.e., NAF and DLS). We demonstrate that circulating PE and EM are strongly and positively correlated with tissue-specific PE and EM measured in NAF and DLS among postmenopausal BRCA1/2 mutation carriers. If confirmed, future etiologic studies could utilize the more readily obtainable serum hormone levels as a reliable surrogate measure of exposure at the tissue level.
Appendix
Available only for authorised users
Literature
1.
Endogenous Hormones Breast Cancer Collaborative Group (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95(16):1218–1226CrossRef
2.
Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059 Erratum appears in Lancet 1997 Nov 15; 350(9089):1484CrossRef
3.
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen–progestin replacement therapy and breast cancer risk. JAMA 283(4):485–491PubMedCrossRef
4.
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA 291(14):1701–1712PubMedCrossRef
5.
Beral V, Banks E, Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360(9337):942–944PubMedCrossRef
6.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRef
7.
Westerlind KC, Gibson KJ, Evans GL, Turner RT (2000) The catechol estrogen, 4-hydroxyestrone, has tissue-specific estrogen actions. J Endocrinol 167(2):281–287PubMedCrossRef
8.
Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270–282PubMedCrossRef
9.
Harvell DM, Strecker TE, Tochacek M, Xie B, Pennington KL, McComb RD, Roy SK, Shull JD (2000) Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci USA 97(6):2779–2784PubMedCrossRef
10.
Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92(9):3650–3657PubMedCrossRef
11.
Turan VK, Sanchez RI, Li JJ, Li SA, Reuhl KR, Thomas PE, Conney AH, Gallo MA, Kauffman FC, Mesia-Vela S (2004) The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17beta-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16alpha-hydroxyestradiol, and 4-hydroxyestrone. J Endocrinol 183(1):91–99PubMedCrossRef
12.
Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203–232PubMedCrossRef
13.
Yang X, Edgerton SM, Kosanke SD, Mason TL, Alvarez KM, Liu N, Chatterton RT, Liu B, Wang Q, Kim A (2003) Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res 63(10):2425–2433PubMed
14.
Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86(3–5):477–486PubMedCrossRef
15.
Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 27:95–112PubMedCrossRef
16.
Cavalieri EL, Rogan EG (2011) Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol 125:169–180PubMedCrossRef
17.
Zhu BT, Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19(1):1–27PubMedCrossRef
18.
Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, Veenstra TD et al (2012) Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 104(4):326–339PubMedCrossRef
19.
Falk R, Gentzschein E, Stanczyk F, Garcia-Closas M, Figueroa J, Ioffe O, Lissowska J, Brinton L, Sherman M (2012) Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. Breast Cancer Res Treat 131(1):287–294PubMedCrossRef
20.
Taioli E, Im A, Xu X, Veenstra T, Ahrendt G, Garte S (2010) Comparison of estrogens and estrogen metabolites in human breast tissue and urine. Reprod Biol Endocrinol 8(1):93PubMedCentralPubMedCrossRef
21.
Castagnetta LAM, Granata OM, Traina A, Ravazzolo B, Amoroso M, Miele M, Bellavia V, Agostara B, Carruba G (2002) Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res 8(10):3146–3155PubMed
22.
Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL (2008) The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 122(9):1949–1957PubMedCrossRef
23.
24.
Chatterton R Jr, Parker N, Habe-Evans M, Bryk M, Scholtens D, Khan S (2010) Breast ductal lavage for assessment of breast cancer biomarkers. Horm Cancer 1(4):197–204PubMedCentralPubMedCrossRef
25.
Berstein LM (2008) Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Futur Oncol 4(1):23–39CrossRef
26.
Lee EY (2008) Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones. Curr Opin Obstet Gynecol 20(1):68–73PubMedCrossRef
27.
28.
Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat M-L, Gyorki DE, Ward T, Partanen A et al (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8):907–913PubMedCrossRef
29.
Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12(1):68–78CrossRef
30.
Chatterton RT Jr, Geiger AS, Gann PH, Khan SA (2003) Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J Steroid Biochem Mol Biol 86(2):159–166PubMedCrossRef
31.
Bhandare D, Nayar R, Bryk M, Hou N, Cohn R, Golewale N, Parker NP, Chatterton RT, Rademaker A, Khan SA (2005) Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomarkers Prev 14:2620–2627PubMedCrossRef
32.
Khan SA, Bhandare D, Chatterton RT Jr (2005) The local hormonal environment and related biomarkers in the normal breast. Endocr Relat Cancer 12(3):497–510PubMedCrossRef
33.
Ernster VL, Wrensch MR, Petrakis NL, King EB, Miike R, Murai J, Goodson WH 3rd, Siiteri PK (1987) Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst 79(5):949–960PubMed
34.
Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH (2005) Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 90(3):1686–1691PubMedCrossRef
35.
Ziegler RG, Faupel-Badger JM, Sue LY, Fuhrman BJ, Falk RT, Boyd-Morin J, Henderson MK, Hoover RN, Veenstra TD, Keefer LK (2010) A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol 121:538–545PubMedCrossRef
36.
Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG (2007) Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography tandem mass spectrometry. Anal Chem 79(20):7813–7821PubMedCrossRef
37.
Loud J, Beckjord E, Nichols K, Peters J, Giusti R, Greene M (2009) Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. BMC Women’s Health 9(1):20PubMedCentralPubMedCrossRef
38.
Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K et al (2010) Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Res Treat 123(1):245–255PubMedCentralPubMedCrossRef
39.
Loud JT, Thiebaut ACM, Abati AD, Filie AC, Nichols K, Danforth D, Giusti R, Prindiville SA, Greene MH (2009) Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? Cancer Epidemiol Biomark Prev 18(4):1243–1251CrossRef
40.
Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O’Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF et al (2001) Ductal lavage for detection of cellular atypia in women at high risk of breast cancer. J Natl Cancer Inst 93(21):1624–1632PubMedCrossRef
41.
Chatterton RT, Khan SA, Heinz R, Ivancic D, Lee O (2010) Patterns of sex steroid hormones in nipple aspirate fluid during the menstrual cycle and after menopause in relation to serum concentrations. Cancer Epidemiol Biomark Prev 19(1):275–279CrossRef
42.
Faupel-Badger JM, Fuhrman BJ, Xu X, Falk RT, Keefer LK, Veenstra TD, Hoover RN, Ziegler RG (2010) Comparison of liquid chromatography–tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens. Cancer Epidemiol Biomark Prev 19(1):292–300CrossRef
Metadata
Title
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers
Authors
Jennifer T. Loud
Gretchen L. Gierach
Timothy D. Veenstra
Roni T. Falk
Kathryn Nichols
Allison Guttmann
Xia Xu
Mark H. Greene
Mitchell H. Gail
Publication date
01-02-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2821-6

Other articles of this Issue 3/2014

Breast Cancer Research and Treatment 3/2014 Go to the issue

Epidemiology

Treatment and outcomes in diabetic breast cancer patients

Preclinical study

Progesterone stimulates progenitor cells in normal human breast and breast cancer cells

Brief Report

Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines

Clinical trial

Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care

Epidemiology

Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy

Epidemiology

Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits